Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community


John M. O’Brien, Jan Elias Hansen


Value in Health, December 2023


In the December 2023 issue of Value in Health, Drs. O'Brien and Hansen offer considerations for CMS on the implementation of the Inflation Reduction Act's Medicare Drug Price Negotiation Program. They outline concerns over CMS’s ambiguous standards, along with the agency's intent to incorporate nonclinical factors unrelated to product value, such as manufacturing costs. The authors warn that these approaches threaten to artificially suppress negotiated prices below fair value and urge more scientific clarity and rigor in the agency’s process, to avoid hindering patient access and the continued development of new treatments, especially in oncology and rare diseases. 

Value in Health December 2023

Read the publication

Value in Health, December 2023